Business Wire
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
➖
AI Sentiment
Neutral
5/10
- Home
- PSNL
PSNL
Personalis Inc.
as of 02-23-2026 12:25pm EST
$8.19
$0.09
-1.15%
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 729.1M | IPO Year: | 2019 |
| Target Price: | $11.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.65 | EPS Growth: | 39.11 |
| 52 Week Low/High: | $2.83 - $11.50 | Next Earning Date: | 03-30-2026 |
| Revenue: | $84,614,000 | Revenue Growth: | 15.15% |
| Revenue Growth (this year): | -15.84% | Revenue Growth (next year): | 16.87% |
| P/E Ratio: | -12.74 | Index: | N/A |
| Free Cash Flow: | -46753000.0 | FCF Growth: | N/A |
AI-Powered PSNL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 73.20%
73.20%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Personalis Inc. (PSNL)
Tachibana Aaron
Sell
CFO AND COO
PSNL Jan 22, 2026
Avg Cost/Share
$11.50
Shares
1,201
Total Value
$13,811.50
Owned After
164,458
SEC Form 4
Tempus Labs, Inc.
Buy
10% Owner
PSNL Dec 22, 2025
Avg Cost/Share
$8.93
Shares
28,000
Total Value
$250,040.00
Owned After
13,039,067
SEC Form 4
Tempus Labs, Inc.
Buy
10% Owner
PSNL Dec 19, 2025
Avg Cost/Share
$8.39
Shares
29,641
Total Value
$248,687.99
Owned After
13,039,067
SEC Form 4
Tempus Labs, Inc.
Buy
10% Owner
PSNL Dec 18, 2025
Avg Cost/Share
$7.91
Shares
31,430
Total Value
$248,611.30
Owned After
13,039,067
SEC Form 4
Tempus Labs, Inc.
Buy
10% Owner
PSNL Dec 17, 2025
Avg Cost/Share
$7.86
Shares
31,650
Total Value
$248,769.00
Owned After
13,039,067
SEC Form 4
Tempus Labs, Inc.
Buy
10% Owner
PSNL Nov 25, 2025
Avg Cost/Share
$10.54
Shares
23,600
Total Value
$250,664.96
Owned After
13,039,067
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tachibana Aaron | PSNL | CFO AND COO | Jan 22, 2026 | Sell | $11.50 | 1,201 | $13,811.50 | 164,458 | |
| Tempus Labs, Inc. | PSNL | 10% Owner | Dec 22, 2025 | Buy | $8.93 | 28,000 | $250,040.00 | 13,039,067 | |
| Tempus Labs, Inc. | PSNL | 10% Owner | Dec 19, 2025 | Buy | $8.39 | 29,641 | $248,687.99 | 13,039,067 | |
| Tempus Labs, Inc. | PSNL | 10% Owner | Dec 18, 2025 | Buy | $7.91 | 31,430 | $248,611.30 | 13,039,067 | |
| Tempus Labs, Inc. | PSNL | 10% Owner | Dec 17, 2025 | Buy | $7.86 | 31,650 | $248,769.00 | 13,039,067 | |
| Tempus Labs, Inc. | PSNL | 10% Owner | Nov 25, 2025 | Buy | $10.54 | 23,600 | $250,664.96 | 13,039,067 |
Latest Personalis Inc. News
PSNL Breaking Stock News: Dive into PSNL Ticker-Specific Updates for Smart Investing
Compare PSNL vs Leading Stocks
See how PSNL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PSNL Personalis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.